Irinotecan plus immunotherapy for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase I/II trial tests how well irinotecan combined with tislelizumab (an immunotherapy) treats advanced stomach or gastroesophageal junction adenocarcinoma. It mainly looks at safety and the best way to use this combination, and may help shrink tumors or slow disease growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach or stomach–food-pipe junction adenocarcinoma that cannot be removed with surgery
- You can do daily activities with minimal limits (ECOG performance status 0–1)
- Your blood counts and organ function (kidneys, liver, and bone marrow) are strong enough for chemotherapy
- You have no serious uncontrolled heart problems, no recent stroke, and your heart tests (ECG) are normal
- You are not pregnant or breastfeeding, and you use birth control as instructed during and after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
This trial tests a new combination treatment with irinotecan liposome for advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line therapy. It aims to see if this treatment can help control the cancer and improve outcomes.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs (adebrelimab, famitinib, and irinotecan) for people with advanced stomach or gastroesophageal junction cancer that got worse after first-line treatment. It may offer a new option if you have already tried standard therapy.
This trial tests a combination of four drugs given before surgery for stomach cancer that can be removed but is considered borderline resectable. The goal is to shrink the tumor to make surgery more successful and potentially improve outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
Hear when a new Gastric Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.